logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Coronary Revascularisation

    FiltersReset Filters
    4 results

    • kengreal

      (cangrelor)
      Chiesi USA, Inc.
      Usage: KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not received a P2Y12 platelet inhibitor and are not on a glycoprotein IIb/IIIa inhibitor.

    • lodoco

      (Colchicine Tablets 0.5 mg)
      AGEPHA Pharma USA, LLC
      Usage: LODOCO is indicated for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular disease risk factors.

    • lovastatin

      (lovastatin)
      Lupin Pharmaceuticals, Inc.
      Usage: Lovastatin is indicated for lowering total and LDL cholesterol levels as part of a treatment strategy in individuals with dyslipidemia at risk for atherosclerotic vascular disease, including those with coronary heart disease and hypercholesterolemia. It is also used for primary prevention of coronary heart disease in certain populations.

    • nexletol

      (Bempedoic Acid)
      Esperion Therapeutics, Inc.
      Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.